165 related articles for article (PubMed ID: 32853683)
1. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
3. 1,2,4-Oxadiazoles identified by virtual screening and their non-covalent inhibition of the human 20S proteasome.
Maréchal X; Genin E; Qin L; Sperandio O; Montes M; Basse N; Richy N; Miteva MA; Reboud-Ravaux M; Vidal J; Villoutreix BO
Curr Med Chem; 2013; 20(18):2351-62. PubMed ID: 23531222
[TBL] [Abstract][Full Text] [Related]
4. Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors.
Maccari R; Ettari R; Adornato I; Naß A; Wolber G; Bitto A; Mannino F; Aliquò F; Bruno G; Nicolò F; Previti S; Grasso S; Zappalà M; Ottanà R
Bioorg Med Chem Lett; 2018 Feb; 28(3):278-283. PubMed ID: 29292224
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes.
Xin BT; de Bruin G; Huber EM; Besse A; Florea BI; Filippov DV; van der Marel GA; Kisselev AF; van der Stelt M; Driessen C; Groll M; Overkleeft HS
J Med Chem; 2016 Aug; 59(15):7177-87. PubMed ID: 27438186
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits.
Maurits E; Degeling CG; Kisselev AF; Florea BI; Overkleeft HS
Chembiochem; 2020 Nov; 21(22):3220-3224. PubMed ID: 32598532
[TBL] [Abstract][Full Text] [Related]
7. Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes.
Ettari R; Cerchia C; Maiorana S; Guccione M; Novellino E; Bitto A; Grasso S; Lavecchia A; Zappalà M
ChemMedChem; 2019 Apr; 14(8):842-852. PubMed ID: 30829448
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
[TBL] [Abstract][Full Text] [Related]
9. Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors.
Nan G; Huang L; Li Y; Yang Y; Yang Y; Li K; Lai F; Chen X; Xiao Z
Eur J Med Chem; 2022 Apr; 234():114252. PubMed ID: 35286927
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits.
Xin BT; Huber EM; de Bruin G; Heinemeyer W; Maurits E; Espinal C; Du Y; Janssens M; Weyburne ES; Kisselev AF; Florea BI; Driessen C; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2019 Feb; 62(3):1626-1642. PubMed ID: 30657666
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
[TBL] [Abstract][Full Text] [Related]
12. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
Li X; Hong D; Zhang M; Xu L; Zhou Y; Li J; Liu T
Eur J Med Chem; 2021 Oct; 221():113556. PubMed ID: 34087498
[TBL] [Abstract][Full Text] [Related]
13. Development of isoquinolinone derivatives as immunoproteasome inhibitors.
Ettari R; Iraci N; Di Chio C; Previti S; Danzè M; Zappalà M
Bioorg Med Chem Lett; 2022 Jan; 55():128478. PubMed ID: 34838650
[TBL] [Abstract][Full Text] [Related]
14. Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors.
Singh PK; Fan H; Jiang X; Shi L; Nathan CF; Lin G
ChemMedChem; 2016 Oct; 11(19):2127-2131. PubMed ID: 27561172
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
17. Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.
Yu J; Liu J; Li D; Xu L; Hong D; Chang S; Xu L; Li J; Liu T; Zhou Y
Eur J Med Chem; 2019 Feb; 164():423-439. PubMed ID: 30611983
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of dipeptides as novel non-covalent 20S proteasome inhibitors.
Yang YJ; Wang K; Yang Y; Lai FF; Chen XG; Xiao ZY
J Asian Nat Prod Res; 2021 May; 23(5):436-451. PubMed ID: 33844614
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Highly Selective Inhibitors of the Human Constitutive Proteasome β5c Chymotryptic Subunit.
Zhan W; Li D; Saha P; Wang R; Zhang H; Ajay AK; Deban C; Sukenick G; Azzi J; Lin G
J Med Chem; 2023 Jan; 66(2):1172-1185. PubMed ID: 36608337
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]